Results 51 to 60 of about 21,299 (206)

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype

Journal of Pharmacological Sciences, 2019
Polymorphisms of cytochrome P450 (CYP) enzymes can affect enzymatic activity, drug metabolism and drug interactions. Although the potential for drug interactions is especially important when co-administering drugs with strong inductive or inhibitory ...
Chiaki Kamiya, Naoki Inui, Akio Hakamata, Sachiko Miyakawa, Shimako Tanaka, Shinya Uchida, Noriyuki Namiki, Keiichi Odagiri, Hiroshi Watanabe   +8 more
doaj   +1 more source

Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy [PDF]

Терапевтический архив, 2017
In current clinical practice, there is no optimal empirical therapy for Helicobacter pylori (H. pylori) infection and there is a progressive decrease in the efficiency of classical eradication therapy (ET) regimens.
I V Maev, D N Andreev
doaj   +1 more source

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

The gut microbiome and drug‐resistant epilepsy: Microbiome–antiseizure medication interactions and implications for pharmacoresistance

Epilepsia Open, EarlyView.
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar, Majd A. AbuAlrob, Musab Ali, Simona Lattanzi, Boulenouar Mesraoua   +4 more
wiley   +1 more source

ASSESSMENT OF THE CLOPIDOGREL ACTION WITH REGARD TO CYP2C19 GENE POLYMORPHISMS IN PATIENTS WITH CORONARY ARTERY DISEASE AFTER IMPLANTATION OF DES STENTS

Евразийский Кардиологический Журнал, 2019
Aim of the work to assess the impact of CYP2C19 polymorphisms, including those of CYP2C19*1, CYP2C19*2, CYP2C19*3 and CYP2C19*17 on clopidogrel response variability in patients undergoing percutaneous coronary intervention (PCI) following DES ...
J. K. Uzokov, B. A. Alyavi, A. X. Abdullaev   +2 more
doaj  

A novel AllGlo probe-quantitative PCR method for detecting single nucleotide polymorphism in CYP2C19 to evaluate the antiplatelet activity of clopidogrel

Scientific Reports
CYP2C19 gene has multiple single nucleotide polymorphism (SNP), which is the major determinant for clopidogrel treatment responses. Therefore, CYP2C19 SNP detection is essential for predicting clopidogrel efficacy.
Hongwei Li, Yizhen Fang, Yongquan Chen, Yuning Lin, Zanxi Fang, Zhiyuan Lin, Huabin Xie, Zhongying Zhang   +7 more
doaj   +1 more source

The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles [PDF]

Drug Metabolism and Disposition, 2015
CYP2C19 rs12769205 alters an intron 2 branch point adenine leading to an alternative mRNA in human liver with complete inclusion of intron 2 (exon 2B). rs12769205 changes the mRNA reading frame, introduces 87 amino acids, and leads to a premature stop codon. The 1000 Genomes project (http://browser.1000genomes.org/index.html) indicated rs12769205 is in
Amarjit S, Chaudhry, Bhagwat, Prasad, Yoshiyuki, Shirasaka, Alison, Fohner, David, Finkelstein, Yiping, Fan, Shuoguo, Wang, Gang, Wu, Eleni, Aklillu, Sarah C, Sim, Kenneth E, Thummel, Erin G, Schuetz   +11 more
openaire   +2 more sources

Plant‐Derived Extracts Disrupt Biofilm Formation and Quorum Sensing in Yersinia enterocolitica: Insights From GC‐MS and Molecular Docking

Food Chemistry International, EarlyView.
The graphical abstract represents how natural plant products that preferentially target the specific receptors of quorum sensing could be developed to combat biofilms linked to Yersinia enterocolitica using the potent abilities of protein–ligand complexes with high docking scores.
Rajendran Thomas, Songeeta Singha, Devarshi Bharadwaj, Abinash Kumar, Dolly Sharma, Sadhana Ojha, Hirakjyoti Das, Vivek Kumar Gupta   +7 more
wiley   +1 more source